Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Medicina (Kaunas). 2011;47(8):413-20. Epub 2011 Nov 18.

Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.

Author information

  • 1Institute of Biotechnology, Vilnius University, V. A. Graičiūno 8, 02241 Vilnius, Lithuania. vilma.petrikaite@bti.vu.lt

Abstract

This review describes the recent progress in the field of heat shock protein 90 (Hsp90) inhibitor design. Hsp90 is a heat shock protein with a molecular weight of approximately 90 kDa. Hsp90 is considered a good anticancer target because its inhibition leads to inactivation of its numerous client proteins participating in various signaling and other processes involved in cancer progression. Numerous Hsp90 inhibitors-leads currently tested in clinical trials are presented in this review. Furthermore, this review emphasizes the application of biophysical binding assays in the development of Hsp90 inhibitors. The binding of designed lead compounds to various Hsp90 constructs is measured by isothermal titration calorimetry and thermal shift assay. These assays provide a detailed energetic insight of the binding reaction, including the enthalpy, entropy, heat capacity, and the Gibbs free energy. A detailed description of the binding energetics helps to extend our knowledge of structure-activity relationships in the design of more potent inhibitors. The most active compounds are then tested for their absorption, distribution, metabolism, elimination, toxicity, and activity against cancer cell lines.

PMID:
22123555
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lithuanian University of Health Sciences
    Loading ...
    Write to the Help Desk